Acute Bronchiolitis: The Less, the Better?


Цитировать

Полный текст

Аннотация

Background:Acute bronchiolitis is a viral infection of the lower respiratory tract affect- ing infants aged under 12 months, variably presenting with respiratory distress, diffuse crackles and inflammatory wheezing. The main causative agent is Respiratory Syncytial Virus (RSV). The diagnosis is clinical and treatment mainly supportive. Despite the availability of more than 30 in- ternational guidelines, consistent management recommendations are lacking and considerable vari- ability in patients’ care persists among different providers.

Objective:To review and describe current knowledge about epidemiology, physiopathology, clin- ic, diagnosis and management of acute bronchiolitis, with particular emphasis on updated evidence and future perspectives in terms of treatment and prevention.

Methods and Results:We searched Cochrane for systematic reviews and PubMed for scientific ar- ticles published in the last 10 years, using a combination of the following search terms: "bronchi- olitis", "respiratory syncytial virus", "epidemiology", "risk factors", "severity", "diagnosis", "clin- ic", "diagnostic imaging", "management", "asthma", "wheezing", "bronchodilator", "steroids", "hypertonic saline", "oxygen", "blood gas analysis", "HHHFNC", "rehydration", "enteral feed- ing", "parenteral hydration", "prevention", "vaccine" and "COVID-19 or SARS-CoV2". We ac- cordingly performed a deep and extensive selection of the most updated and considerable litera- ture on the matter, summarizing the most significant evidence concerning all aspects of acute bron- chiolitis (epidemiology, clinic, diagnosis, management and prevention). Furthermore, we ex- amined references and available guidelines from UK, USA, Canada, Italy and Spain. Results are extensively discussed below.

Conclusion:Although acute bronchiolitis has been a widely known disease for decades, its thera- peutic approach remained unchanged and essentially limited to respiratory and metabolic support. Despite the abundance of studies, there is no significant evidence concerning therapeutic alterna- tives (e.g. steroids, inhaled hypertonic solution), which are therefore not recommended. Accord- ing to most recent data, "acute bronchiolitis" definition encompasses a plethora of different clini- cal entities related to each subject’s genetic and immune predisposition. Therefore, future research should focus on the precise characterization of such subcategories in order to individualize thera- peutic management and ensure the most appropriate evidence-based care.

Об авторах

Fabrizio Virgili

Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome

Автор, ответственный за переписку.
Email: info@benthamscience.net

Raffaella Nenna

Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome

Email: info@benthamscience.net

Greta Di Mattia

Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome

Email: info@benthamscience.net

Luigi Matera

Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome

Email: info@benthamscience.net

Laura Petrarca

Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome

Email: info@benthamscience.net

Maria Conti

Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome

Email: info@benthamscience.net

Fabio Midulla

Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome

Email: info@benthamscience.net

Список литературы

  1. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. Lancet 2017; 390(10098): 946-58. doi: 10.1016/S0140-6736(17)30938-8 PMID: 28689664
  2. Nicolai A, Ferrara M, Schiavariello C, et al. Viral bronchiolitis in children: A common condition with few therapeutic options. Early Hum Dev 2013; 89(Suppl. 3): S7-S11. doi: 10.1016/j.earlhumdev.2013.07.016 PMID: 23972293
  3. Sander B, Finkelstein Y, Lu H, et al. Healthcare cost attributable to bronchiolitis: A population-based cohort study. PLoS One 2021; 16(12): e0260809. doi: 10.1371/journal.pone.0260809 PMID: 34855892
  4. Vandini S, Biagi C, Lanari M. Respiratory syncytial virus: The influence of serotype and genotype variability on clinical course of infection. Int J Mol Sci 2017; 18(8): 1717. doi: 10.3390/ijms18081717 PMID: 28783078
  5. Silver AH, Nazif JM. Bronchiolitis. Pediatr Rev 2019; 40(11): 568-76. doi: 10.1542/pir.2018-0260 PMID: 31676530
  6. Bohmwald K, Espinoza J, Rey-Jurado E, et al. Human respiratory syncytial virus: Infection and pathology. Semin Respir Crit Care Med 2016; 37(4): 522-37. doi: 10.1055/s-0036-1584799 PMID: 27486734
  7. García CG, Bhore R, Soriano-Fallas A, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics 2010; 126(6): e1453-60. doi: 10.1542/peds.2010-0507 PMID: 21098154
  8. Milani GP, Bollati V, Ruggiero L, et al. Bronchiolitis and SARS-CoV-2. Arch Dis Child 2021; 106(10): 999-1001. doi: 10.1136/archdischild-2020-321108 PMID: 33707224
  9. Andina-Martinez D, Alonso-Cadenas JA, Cobos-Carrascosa E, et al. SARS-CoV-2 acute bronchiolitis in hospitalized children: Neither frequent nor more severe. Pediatr Pulmonol 2022; 57(1): 57-65. doi: 10.1002/ppul.25731 PMID: 34664782
  10. Flores-Pérez P, Gerig N, Cabrera-López MI, de Unzueta-Roch JL, del Rosal T, Calvo C. Acute bronchiolitis during the COVID-19 pandemic. Enferm Infecc Microbiol Clin 2022; 40(10): 572-5. doi: 10.1016/j.eimc.2021.06.012 PMID: 34219854
  11. Petrarca L, Nenna R, Frassanito A, et al. Acute bronchiolitis: Influence of viral co-infection in infants hospitalized over 12 consecutive epidemic seasons. J Med Virol 2018; 90(4): 631-8. doi: 10.1002/jmv.24994 PMID: 29226974
  12. Fretzayas A, Moustaki M. Etiology and clinical features of viral bronchiolitis in infancy. World J Pediatr 2017; 13(4): 293-9. doi: 10.1007/s12519-017-0031-8 PMID: 28470580
  13. Janet S, Broad J, Snape MD. Respiratory syncytial virus seasonality and its implications on prevention strategies. Hum Vaccin Immunother 2018; 14(1): 234-44. doi: 10.1080/21645515.2017.1403707 PMID: 29194014
  14. Barbati F, Moriondo M, Pisano L, et al. Epidemiology of respiratory syncytial virus-related hospitalization over a 5-year period in italy: Evaluation of seasonality and age distribution before vaccine Introduction. Vaccines 2020; 8(1): 15. doi: 10.3390/vaccines8010015 PMID: 31947976
  15. Van Brusselen D, De Troeyer K, ter Haar E, et al. Bronchiolitis in COVID-19 times: A nearly absent disease? Eur J Pediatr 2021; 180(6): 1969-73. doi: 10.1007/s00431-021-03968-6 PMID: 33517482
  16. Jiang X, Wang T, Dai G, et al. Clinical characteristics and etiology of children with bronchiolitis before and during the COVID-19 pandemic in Suzhou, China. Front Pediatr 2022; 10: 974769. doi: 10.3389/fped.2022.974769 PMID: 36452360
  17. Nenna R, Matera L, Pierangeli A, et al. First COVID-19 lockdown resulted in most respiratory viruses disappearing among hospitalised children, with the exception of rhinoviruses. Acta Paediatr 2022; 111(7): 1399-403. doi: 10.1111/apa.16326 PMID: 35266576
  18. Foley DA, Yeoh DK, Minney-Smith CA, et al. The Interseasonal resurgence of respiratory syncytial virus in australian children following the reduction of coronavirus disease 2019-related public health measures. Clin Infect Dis 2021; 73(9): e2829-30. doi: 10.1093/cid/ciaa1906 PMID: 33594407
  19. Bermúdez Barrezueta L, Gutiérrez Zamorano M, López-Casillas P, Brezmes-Raposo M, Sanz Fernández I, Pino Vázquez MA. Influence of the COVID-19 pandemic on the epidemiology of acute bronchiolitis. Enferm Infecc Microbiol Clin 2023; 41(6): 348-51.
  20. Gill PJ, Chanchlani N, Mahant S. Bronchiolitis. CMAJ 2022; 194(6): E216. doi: 10.1503/cmaj.211810 PMID: 35165133
  21. Guitart C, Bobillo-Perez S, Alejandre C, et al. Bronchiolitis, epidemiological changes during the SARS-CoV-2 pandemic. BMC Infect Dis 2022; 22(1): 84. doi: 10.1186/s12879-022-07041-x PMID: 35073855
  22. Fan R, Wen B, Liu W, et al. Altered regulatory cytokine profiles in cases of pediatric respiratory syncytial virus infection. Cytokine 2018; 103: 57-62. doi: 10.1016/j.cyto.2017.12.028 PMID: 29324262
  23. Sebina I, Phipps S. The contribution of neutrophils to the pathogenesis of RSV bronchiolitis. Viruses 2020; 12(8): 808. doi: 10.3390/v12080808 PMID: 32726921
  24. Dalziel SR, Haskell L, O’Brien S, et al. Bronchiolitis. Lancet 2022; 400(10349): 392-406. doi: 10.1016/S0140-6736(22)01016-9 PMID: 35785792
  25. Eber E, Midulla F. ERS Handbook of Paediatric Respiratory Medicine. (2nd ed..), European Respiratory Society 2021. doi: 10.1183/9781849841313.eph01
  26. Mitri EJ, Zheng DX, Garg V, et al. Blood eosinophils, specific immunoglobulin E, and bronchiolitis severity. Pediatr Pulmonol 2021; 56(9): 2997-3004. doi: 10.1002/ppul.25543 PMID: 34156171
  27. Raita Y, Pérez-Losada M, Freishtat RJ, et al. Integrated omics endotyping of infants with respiratory syncytial virus bronchiolitis and risk of childhood asthma. Nat Commun 2021; 12(1): 3601. doi: 10.1038/s41467-021-23859-6 PMID: 34127671
  28. Jartti T, Smits HH, Bønnelykke K, et al. Bronchiolitis needs a revisit: Distinguishing between virus entities and their treatments. Allergy 2019; 74(1): 40-52. doi: 10.1111/all.13624 PMID: 30276826
  29. Dumas O, Mansbach JM, Jartti T, et al. A clustering approach to identify severe bronchiolitis profiles in children. Thorax 2016; 71(8): 712-8. doi: 10.1136/thoraxjnl-2016-208535 PMID: 27339060
  30. Cangiano G, Nenna R, Frassanito A, et al. Bronchiolitis: Analysis of 10 consecutive epidemic seasons. Pediatr Pulmonol 2016; 51(12): 1330-5. doi: 10.1002/ppul.23476 PMID: 27228123
  31. Petrarca L, Nenna R, Di Mattia G, et al. Bronchiolitis phenotypes identified by latent class analysis may influence the occurrence of respiratory sequelae. Pediatr Pulmonol 2022; 57(3): 616-22. doi: 10.1002/ppul.25799 PMID: 34931488
  32. Schroeder AR, Mansbach JM, Stevenson M, et al. Apnea in children hospitalized with bronchiolitis. Pediatrics 2013; 132(5): e1194-201. doi: 10.1542/peds.2013-1501 PMID: 24101759
  33. National Institute for Health and Care Excellence (NICE). Bronchiolitis in children: Diagnosis and management. 2021. Available from:https://www.nice.org.uk/guidance/ng9 (cited: Dec 18, 2022)
  34. Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. Lancet 2017; 389(10065): 211-24. doi: 10.1016/S0140-6736(16)30951-5 PMID: 27549684
  35. Mansbach JM, Clark S, Piedra PA, et al. Hospital course and discharge criteria for children hospitalized with bronchiolitis. J Hosp Med 2015; 10(4): 205-11. doi: 10.1002/jhm.2318 PMID: 25627657
  36. Hancock DG, Charles-Britton B, Dixon DL, Forsyth KD. The heterogeneity of viral bronchiolitis: A lack of universal consensus definitions. Pediatr Pulmonol 2017; 52(9): 1234-40. doi: 10.1002/ppul.23750 PMID: 28672069
  37. Rodriguez-Martinez CE, Sossa-Briceño MP, Nino G. Systematic review of instruments aimed at evaluating the severity of bronchiolitis. Paediatr Respir Rev 2018; 25: 43-57. PMID: 28258885
  38. Midulla F, Petrarca L, Frassanito A, Di Mattia G, Zicari AM, Nenna R. Bronchiolitis clinics and medical treatment. Minerva Pediatr 2018; 70(6): 600-11. doi: 10.23736/S0026-4946.18.05334-3 PMID: 30334624
  39. Friedman JN, Davis T, Somaskanthan A, Ma A. Avoid doing chest x rays in infants with typical bronchiolitis. BMJ 2021; 375: e064132. doi: 10.1136/bmj-2021-064132 PMID: 34686495
  40. Sarmiento L, Rojas-Soto GE, Rodríguez-Martínez CE. Predictors of inappropriate use of diagnostic tests and management of bronchiolitis. BioMed Res Int 2017; 2017: 1-6. doi: 10.1155/2017/9730696 PMID: 28758127
  41. Supino MC, Buonsenso D, Scateni S, et al. Point-of-care lung ultrasound in infants with bronchiolitis in the pediatric emergency department: A prospective study. Eur J Pediatr 2019; 178(5): 623-32. doi: 10.1007/s00431-019-03335-6 PMID: 30747262
  42. La Regina DP, Bloise S, Pepino D, et al. Lung ultrasound in bronchiolitis. Pediatr Pulmonol 2021; 56(1): 234-9. doi: 10.1002/ppul.25156 PMID: 33151023
  43. Stollar F, Alcoba G, Gervaix A, Argiroffo CB. Virologic testing in bronchiolitis: Does it change management decisions and predict outcomes? Eur J Pediatr 2014; 173(11): 1429-35. doi: 10.1007/s00431-014-2334-2 PMID: 24858463
  44. Librizzi J, McCulloh R, Koehn K, Alverson B. Appropriateness of testing for serious bacterial infection in children hospitalized with bronchiolitis. Hosp Pediatr 2014; 4(1): 33-8. doi: 10.1542/hpeds.2013-0073 PMID: 24435599
  45. McDaniel CE, Ralston S, Lucas B, Schroeder AR. Association of diagnostic criteria with urinary tract infection prevalence in bronchiolitis. JAMA Pediatr 2019; 173(3): 269-77. doi: 10.1001/jamapediatrics.2018.5091 PMID: 30688987
  46. Mahant S, Wahi G, Bayliss A, et al. Intermittent vs continuous pulse oximetry in hospitalized infants with stabilized bronchiolitis. JAMA Pediatr 2021; 175(5): 466-74. doi: 10.1001/jamapediatrics.2020.6141 PMID: 33646286
  47. Nagakumar P, Doull I. Current therapy for bronchiolitis. Arch Dis Child 2012; 97(9): 827-30. doi: 10.1136/archdischild-2011-301579 PMID: 22734014
  48. Oakley E, Borland M, Neutze J, et al. Nasogastric hydration versus intravenous hydration for infants with bronchiolitis: A randomised trial. Lancet Respir Med 2013; 1(2): 113-20. doi: 10.1016/S2213-2600(12)70053-X PMID: 24429091
  49. Oakley E, Bata S, Rengasamy S, et al. Nasogastric hydration in infants with bronchiolitis less than 2 months of age. J Pediatr 2016; 178: 241-245.e1. doi: 10.1016/j.jpeds.2016.07.012 PMID: 27522439
  50. Van Ginderdeuren F, Vandenplas Y, Deneyer M, Vanlaethem S, Buyl R, Kerckhofs E. Effectiveness of airway clearance techniques in children hospitalized with acute bronchiolitis. Pediatr Pulmonol 2017; 52(2): 225-31. doi: 10.1002/ppul.23495 PMID: 27254132
  51. Cunningham S, Rodriguez A, Adams T, et al. Oxygen saturation targets in infants with bronchiolitis (BIDS): A double-blind, randomised, equivalence trial. Lancet 2015; 386(9998): 1041-8. doi: 10.1016/S0140-6736(15)00163-4 PMID: 26382998
  52. Lin J, Zhang Y, Xiong L, Liu S, Gong C, Dai J. High-flow nasal cannula therapy for children with bronchiolitis: A systematic review and meta-analysis. Arch Dis Child 2019; 104(6): 564-76. doi: 10.1136/archdischild-2018-315846 PMID: 30655267
  53. O’Brien S, Craig S, Babl FE, Borland ML, Oakley E, Dalziel SR. ‘Rational use of high-flow therapy in infants with bronchiolitis. What do the latest trials tell us?’ A paediatric research in emergency departments international collaborative perspective. J Paediatr Child Health 2019; 55(7): 746-52. doi: 10.1111/jpc.14496 PMID: 31270867
  54. Durand P, Guiddir T, Kyheng C, et al. A randomised trial of high-flow nasal cannula in infants with moderate bronchiolitis. Eur Respir J 2020; 56(1): 1901926. doi: 10.1183/13993003.01926-2019 PMID: 32381496
  55. Kepreotes E, Whitehead B, Attia J, et al. High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): An open, phase 4, randomised controlled trial. Lancet 2017; 389(10072): 930-9. doi: 10.1016/S0140-6736(17)30061-2 PMID: 28161016
  56. Ralston SL. High-flow nasal cannula therapy for pediatric patients with bronchiolitis. JAMA Pediatr 2020; 174(7): 635-6. doi: 10.1001/jamapediatrics.2020.0040 PMID: 32202628
  57. Dafydd C, Saunders BJ, Kotecha SJ, Edwards MO. Efficacy and safety of high flow nasal oxygen for children with bronchiolitis: Systematic review and meta-analysis. BMJ Open Respir Res 2021; 8(1): e000844. doi: 10.1136/bmjresp-2020-000844 PMID: 34326153
  58. Tortosa F, Izcovich A, Carrasco G, Varone G, Haluska P, Sanguine V. High-flow oxygen nasal cannula for treating acute bronchiolitis in infants: A systematic review and meta-analysis. Medwave 2021; 21(4): e8190. doi: 10.5867/medwave.2021.04.8190 PMID: 34086669
  59. Lipshaw MJ, Florin TA. "Don’t Just Do Something, Stand There": Embracing deimplementation of bronchiolitis therapeutics. Pediatrics 2021; 147(5): e2020048645. doi: 10.1542/peds.2020-048645 PMID: 33893228
  60. Elliott SA, Gaudet LA, Fernandes RM, et al. Comparative efficacy of bronchiolitis interventions in acute care: A network meta-analysis. Pediatrics 2021; 147(5): e2020040816. doi: 10.1542/peds.2020-040816 PMID: 33893229
  61. Nordal EB, Granslo HN, Esaiassen E, Leknessund CBB, Forsdahl BA. Bronchiolitis should not be treated with glucocorticoids or antibiotics. Tidsskr Nor Laegeforen 2021; 141(2) doi: 10.4045/tidsskr.21.0862 PMID: 35107946
  62. Heikkilä P, Korppi M. Hypertonic saline in bronchiolitis: An updated meta-analysis. Arch Dis Child 2021; 106(1): 102.2-. doi: 10.1136/archdischild-2020-319048 PMID: 32213483
  63. Plint AC, Johnson DW, Patel H, et al. Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med 2009; 360(20): 2079-89. doi: 10.1056/NEJMoa0900544 PMID: 19439742
  64. Manti S, Staiano A, Orfeo L, et al. UPDATE - 2022 Italian guidelines on the management of bronchiolitis in infants. Ital J Pediatr 2023; 49(1): 19. doi: 10.1186/s13052-022-01392-6 PMID: 36765418
  65. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2014; 2014(6): CD001266. PMID: 24937099
  66. Chung A, Reeves RM, Nair H, et al. Hospital admission trends for bronchiolitis in Scotland, 2001-2016: A national retrospective observational study. J Infect Dis 2020; 222(Suppl. 7): S592-8. doi: 10.1093/infdis/jiaa323 PMID: 32794556
  67. Hasegawa K, Mansbach JM, Ajami NJ, et al. Association of nasopharyngeal microbiota profiles with bronchiolitis severity in infants hospitalised for bronchiolitis. Eur Respir J 2016; 48(5): 1329-39. doi: 10.1183/13993003.00152-2016 PMID: 27799386
  68. Norlander AE, Peebles RS Jr. Innate type 2 responses to respiratory syncytial virus infection. Viruses 2020; 12(5): 521. doi: 10.3390/v12050521 PMID: 32397226
  69. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368(19): 1791-9. doi: 10.1056/NEJMoa1211917 PMID: 23656644
  70. Brunwasser SM, Snyder BM, Driscoll AJ, et al. Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: A systematic review and meta-analysis. Lancet Respir Med 2020; 8(8): 795-806. doi: 10.1016/S2213-2600(20)30109-0 PMID: 32763206
  71. Midulla F, Nicolai A, Ferrara M, et al. Recurrent wheezing 36 months after bronchiolitis is associated with rhinovirus infections and blood eosinophilia. Acta Paediatr 2014; 103(10): 1094-9. doi: 10.1111/apa.12720 PMID: 24948158
  72. Wang G, Han D, Jiang Z, Li M, Yang S, Liu L. Association between early bronchiolitis and the development of childhood asthma: A meta-analysis. BMJ Open 2021; 11(5): e043956. doi: 10.1136/bmjopen-2020-043956 PMID: 34049905
  73. Mooney K, Melvin M, Douglas T. Ribavirin: The need for exposure precautions. Clin J Oncol Nurs 2014; 18(5): E93-6. doi: 10.1188/14.CJON.E93-E96 PMID: 25253120
  74. Noor A, Krilov LR. Respiratory syncytial virus vaccine: Where are we now and what comes next? Expert Opin Biol Ther 2018; 18(12): 1247-56. doi: 10.1080/14712598.2018.1544239 PMID: 30426788
  75. Brady MT, Byington CL, Davies HD, et al. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134(2): e620-38. doi: 10.1542/peds.2014-1666 PMID: 25070304
  76. Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev 2021; 11(11): CD013757. PMID: 34783356
  77. Gonzales T, Bergamasco A, Cristarella T, et al. Effectiveness and safety of palivizumab for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus: A systematic review. Am J Perinatol 2023. doi: 10.1055/a-1990-2633 PMID: 36452969
  78. Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med 2017; 9(388): eaaj1928. doi: 10.1126/scitranslmed.aaj1928
  79. Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020; 383(5): 415-25. doi: 10.1056/NEJMoa1913556 PMID: 32726528
  80. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 2022; 386(9): 837-46. doi: 10.1056/NEJMoa2110275 PMID: 35235726
  81. Maas BM, Lommerse J, Plock N, et al. Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis. EBioMedicine 2021; 73: 103651. doi: 10.1016/j.ebiom.2021.103651 PMID: 34775220
  82. Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within reach: The vaccine and monoclonal antibody landscape. Lancet Infect Dis 2023; 23(1): e2-e21. doi: 10.1016/S1473-3099(22)00291-2 PMID: 35952703
  83. Aranda SS, Polack FP. Prevention of pediatric respiratory syncytial virus lower respiratory tract illness: perspectives for the next decade. Front Immunol 2019; 10: 1006. doi: 10.3389/fimmu.2019.01006 PMID: 31134078
  84. Smith TRF, Schultheis K, Broderick KE. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods. Hum Vaccin Immunother 2017; 13(11): 2626-9. doi: 10.1080/21645515.2017.1363134 PMID: 28881156
  85. Scheltema NM, Kavelaars XM, Thorburn K, et al. Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy. Vaccine 2018; 36(31): 4693-700. doi: 10.1016/j.vaccine.2018.06.021 PMID: 29941327
  86. Pfizer Inc. Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate. 2022. Available from:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-global (cited: Dec 18, 2022)
  87. Achten NB, Wu P, Bont L, et al. Interference between respiratory syncytial virus and human rhinovirus infection in infancy. J Infect Dis 2017; 215(7): 1102-6. doi: 10.1093/infdis/jix031 PMID: 28368456

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Bentham Science Publishers, 2024